MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MPLT had $25,893K increase in cash & cash equivalents over the period. -$91,405K in free cash flow.

Cash Flow Overview

Change in Cash
$25,893K
Free Cash flow
-$91,405K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Net loss
-81,604
Depreciation
438
Stock-based compensation expense
485
Net amortization of premiums and accretion of discounts on investments
660
Common stock issued to neurosolis
496
Non-cash lease expense
644
Loss from disposal and write-off of equipment
-7
Prepaid expenses and other assets
10,774
Accounts payable
491
Accrued expenses
1,775
Operating lease liability
-573
Deferred grant earnings
-2,033
Net cash used in operating activities
-91,308
Purchases of short-term and long-term investments
142,057
Maturities of marketable debt securities
61,500
Purchases of property and equipment
97
Net cash used in investing activities
-80,654
Payments of deferred financing costs
1,127
Proceeds from issuance of series d redeemable convertible preferred stock, net of issuance costs
198,870
Proceeds from exercise of stock options
112
Net cash provided by financing activities
197,855
Increase (decrease) in cash, cash equivalents, and restricted cash
25,893
Cash and cash equivalents at beginning of period
38,460
Cash and cash equivalents at end of period
64,353
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

MapLight Therapeutics, Inc. (MPLT)

MapLight Therapeutics, Inc. (MPLT)